Small Cap Awards Nominees:

Speakers

Sara-Louise Porter

Director & Head of Business Development

Sara-Louise is a Director and the Head of Business Development at Aquis Stock Exchange: a UK-based primary and secondary market for equity and debt securities which focuses on listing and developing growth companies on the public markets.

Passionate about helping companies to find the scale-up capital they need to develop and grow, Sara-Louise has assisted several hundred dynamic businesses to navigate the complex requirements of a primary market and capital markets journey.

Sara-Louise has over 20 years’ experience in public markets, with roles spanning events and marketing as well as her primary focus on relationship management and business development. She is a UK market expert, having spent the majority of her career based in London, but has also overseen international dual-listings and spent time working on international account management from Hong Kong.

Sara-Louise is a supporter of companies who deliver social and environmental impact alongside their financial performance, and champions the role of public markets in ensuring companies manage and disclose their broader responsibilities to all stakeholders. A vocal advocate for diversity and inclusion, Sara-Louise has led multiple formal and informal Women in Business networks and initiatives.

Jonathan Neame

Managing Director & Chief Executive

Jonathan Neame was educated at Harrow School, Pembroke College Cambridge, The City University and Inns of Court School of Law. He achieved 2.1 MA Cantab Classics; Diploma in Legal Education and is a Barrister at Law.

After qualifying as a Barrister he joined the COBA Group, London specialists in mergers and acquisitions work, as a Strategic Consultant. Jonathan joined Shepherd Neame in 1991 as Company Secretary. In 1999 he became Managing Director and Chief Executive in 2003 until today.

He was Chairman of the British Beer and Pub Association from 2012 to 2015 and a Non-Executive Director of the St Austell Brewery Company Ltd from 2002 until May 2018. He was Master of the Worshipful Company of Brewers in 2022-2023. He is currently the Vice President of the Brewers of Europe.

He was a Chairman of Visit Kent from 2015 till 2020 and a Chairman a Trustee of the Leeds Castle Foundation from 2011 to 2022.

He is a Deputy Lieutenant of Kent and High Sheriff-in-Nomination (Kent) for 2025-26. He was awarded an Honorary Doctorate from the University of Kent in 2016.

Jonathan is married to Lucie and they have one daughter, Violette.His interests include cricket, real tennis, skiing, country pursuits, walking and cycling.

Ian Foley

Chief Executive Officer 

Equipmake is a UK-based engineering specialist with over 20 years’ experience developing and producing industry-leading electrification products. At the forefront of the transition from fossil-fuelled to zero-emission powertrains, Equipmake has emerged as a leader in the production of complete electric vehicle (EV) drivetrains for high-performance and heavy commercial vehicles.

Ben Richardson

CEO

A former Chief Operating Officer and Chief Commercial Officer with 25+ years industry experience including ~16 years at Deutsche Bank in various senior roles. Ben has a proven track record of leading and delivering lasting success. Ben has wide ranging experience from roles in a variety of global locations including USA, The Netherlands and Australia, specialising in Sales / Business Development, Risk Management, Governance and strategic transformations​

The world’s reliance on hydrocarbon liquid fuels continues to grow despite the success in many forms of renewable energy. SulNOx Group Plc (Ticker: SNOX) specialises in inventing immediate and responsible solutions towards decarbonisation. Our patented, Greentech fuel conditioners are unique in reducing fuel consumption and the production of harmful, environmentally damaging greenhouse gas emissions such as NOx (>30%), whilst also reducing deadly Particulate Matter (PMs), including soot and smoke (PM_2.5 ↓60+% and PM₁₀ ↓50+%).

Simple to use and immediately effective, SulNOx has successfully sold our high margin, subscription products in 34 countries and are now demonstrating improving revenues with back-to-back record trading quarters, driven by expanding sales in Africa and the marine sector. Unaudited full year 2024 revenues were £555,290, almost triple the previous year (£203,061) with unaudited Q4 revenues of £314,995, up 201% on Q3 (£104,572) and up 282% vs Q4 2023 (£82,546).

How it Works: SulNOxEco™ Fuel Conditioners enhance all gasoline/petrol, diesel, marine fuels and biofuels by improving the burn profile. Given the amount of fuel consumption and emissions depends on the quality of combustion, SulNOx’s unique emulsification technologies promote cleaner combustion to optimize energy output, meaning reduced fuel consumption (typically between 8% and 10%). SulNOx also adds natural lubricity (now lacking with the removal of sulphur in fuel) and provides detergency to clean engines – leading to further savings, such as AdBlue reductions) and other mechanical benefits.

What sets SulNOx apart: Traditional fuel additives are often fossil fuel-based formulations from waste refinery products and solvents such as naphthalene or xylene. They work like adding lighter fluid to a fire to make the combustion burn harder and brighter. This is neither a solution for decarbonisation nor does it help reduce the harmful impact that fossil fuel combustion is having on air quality and the environment.

SulNOx has partnered with EcoVadis Platinum rated Nouryon BV (formerly Akzo Nobel) to produce our Greentech products given their global scale and reputation.

SulNOx is able to improve 70% of every barrel of oil and all internal combustion engines across diverse sectors with global applicability. Industries which benefit include fuel storage and distribution (petrol stations), transport (haulage, rail, buses/coaches, taxis etc.), marine, mining & construction and waste oil reclamation.

SulNOx is a UK Public Limited Company, formed in 2012, trading on the pan-European Apex segment of the AQSE (Aquis Stock Exchange) growth market with ticker SNOX.

For more information, please contact SulNOx through the website at https://sulnoxgroup.com or email info@sulnoxgroup.com.

Adam Binns

CEO

Adam joined One Health Group as Project Director & COO in January 2018, taking on the role of FD & COO in May 2018 and CEO in July 2019. Prior to joining One Health, Adam worked extensively in senior financial, operational and commercial roles across retail, logistics and manufacturing. He takes great pride in recognising and developing talent and bringing out the best in his senior team and colleagues. Adam is looking forward to further developing One Health’s relationship with the NHS across multiple geographies and extending the delivery of free, first-class clinical care to a wider population of NHS patients, supporting the drive to reduce record post-pandemic waiting lists. He is a member of the Chartered Institute of Management Accountants.

Derek Bickerstaff

Founder and Non-Executive Chairman

Derek is a (recently retired) Orthopaedic Consultant Surgeon who specialised in knee surgery, with senior positions in Sheffield NHS teaching hospitals. He founded One Health after leaving the NHS in 2000 in pursuit of a better way of operating through outsourcing services from the NHS. He is recognised as one of the UK’s leading knee surgeons and took referrals nationally and internationally including many high-profile athletes. He held appointments as the Knee Tutor at the Royal College of Surgeons of England and served as an executive member of the British Association of Surgery of the Knee. He has also served on the board of the Journal of Bone and Joint Surgery. Derek is frequently invited to lecture on knee surgery at national and international meetings.

Tim McCarthy

Chairman

Tim has over 40 years’ international senior level business experience in the Healthcare, Biotech and Technology sectors.

Tim joined Incanthera in 2015 to provide corporate experience and guidance in preparation for the company’s flotation on the Aquis Stock Exchange in 2020. Incanthera plc (AQSE: INC), is a specialist company focused on innovative technologies in oncology and dermatology.

He is also CEO of ImmuPharma plc, a specialist drug discovery and development company and Chairman of 4basebio PLC, a company developing next generation gene therapy technologies and solutions, both of which are quoted on AIM.

Tim is a former CEO and Finance Director of a number of public and private companies, including Alizyme plc and Peptide Therapeutics Group plc. He has also co-founded a number of healthcare and biotechnology companies. A Fellow of the Association of Chartered Certified Accountants, he also has an MBA from Cranfield School of Management.

Tim is married, with three grown up children and two grandchildren. His interests include Peterborough United football club, yoga and pursuit of current trends across the health and wellness space.